IPO registrations (S-1, F-1) · Registrants
MACROGENICS INC
- SEC CIK
- 1125345 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2013-09-04, last 2014-02-12; 2 initial registrations, 6 amendments
- Outcome
- Final prospectus filed 2013-10-11; declared effective 2013-10-09
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 9704 MEDICAL CENTER DRIVE, Rockville, MD 20850
- Ticker
- MGNX (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- MACROGENICS INC on the corporate pages
Offering terms
- Final price
- $16.00 per share (424B4 filed 2013-10-11, an initial public offering)
- Shares sold
- 5,000,000
- Gross proceeds
- $80,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol MGNX
- Lead underwriters
- Merrill Lynch; Leerink Partners (1,500,000 shares)
- Syndicate
- BofA Securities; Stifel (600,000); Lazard (500,000); Wedbush Securities (500,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Federal award recipient: MACROGENICS, INC. Fuzzy (name and state)
- SEC filer: MACROGENICS INC EXACT (CIK (EXACT))
- Person page: David C Stump MD Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 14
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2013-09-04 | S-1 | S-1 (registration) | MACROGENICS INC | 0001193125-13-357191 ↗ |
| 2013-09-20 | S-1/A | S-1/A (amendment) | MACROGENICS INC | 0001193125-13-373552 ↗ |
| 2013-10-01 | S-1/A | S-1/A (amendment) | MACROGENICS INC | 0001193125-13-386872 ↗ |
| 2013-10-04 | S-1/A | S-1/A (amendment) | MACROGENICS INC | 0001193125-13-391750 ↗ |
| 2013-10-09 | S-1/A | S-1/A (amendment) | MACROGENICS INC | 0001193125-13-394786 ↗ |
| 2013-10-09 | EFFECT | EFFECT (declared effective) | MACROGENICS INC | 9999999995-13-002931 ↗ |
| 2013-10-11 | 424B4 | 424B4 (final prospectus) | MACROGENICS INC | 0001193125-13-397751 ↗ |
| 2014-01-30 | S-1 | S-1 (registration) | MACROGENICS INC | 0001193125-14-027049 ↗ |
| 2014-02-10 | S-1/A | S-1/A (amendment) | MACROGENICS INC | 0001193125-14-043144 ↗ |
| 2014-02-12 | S-1/A | S-1/A (amendment) | MACROGENICS INC | 0001193125-14-048113 ↗ |
| 2014-02-12 | S-1MEF | S-1MEF (added securities) | MACROGENICS INC | 0001193125-14-048875 ↗ |
| 2014-02-12 | EFFECT | EFFECT (declared effective) | MACROGENICS INC | 9999999995-14-000433 ↗ |
| 2014-02-13 | 424B4 | 424B4 (final prospectus) | MACROGENICS INC | 0001193125-14-050806 ↗ |
| 2014-11-21 | EFFECT | EFFECT (declared effective) | MACROGENICS INC | 9999999995-14-003495 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2013-10-09 | S-1/A | registration statement | $16.00 | 5,000,000 | $80,000,000 | Nasdaq MGNX | 6 | primary document; price sentence, shares headline, proceeds computed, cover names 5 | document ↗ | |
| 2013-10-11 | 424B4 | final prospectus | $16.00 | 5,000,000 | $80,000,000 | Nasdaq MGNX | 6 | primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 5 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG | TenPercentOwner | 2 | 2013 | ||
| ALTA BIOPHARMA PARTNERS III LP | TenPercentOwner | 2 | 2013 | ||
| ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC | TenPercentOwner | 2 | 2013 | ||
| BONDERMAN DAVID | Other; TenPercentOwner | 2 | 2013 | ||
| Bonvini Ezio | Officer | Senior V P, Research; Senior VP, Research; Sr VP, Research & CSO | 58 | 2013–2026 | |
| CASH HARVEY B | TenPercentOwner | 2 | 2013 | ||
| Cilinski Lynn | Officer | V P, Controller and Treasurer; VP, Controller and Treasurer | 20 | 2013–2024 | |
| Costa Paulo F | Director | 11 | 2013–2021 | ||
| COULTER JAMES G | Other; TenPercentOwner | 2 | 2013 | ||
| Galbraith Kenneth | Director | 12 | 2013–2021 | ||
| GIANOS PHILIP T | TenPercentOwner | 2 | 2013 | ||
| HEDRICK W SCOTT | TenPercentOwner | 2 | 2013 | ||
| Holmes W Stephen | TenPercentOwner | 2 | 2013 | ||
| HURWITZ EDWARD | Director | 20 | 2013–2026 | ||
| INTERWEST INVESTORS Q VIII LP | TenPercentOwner | 2 | 2013 | ||
| INTERWEST INVESTORS VIII L P | TenPercentOwner | 2 | 2013 | ||
| InterWest Management Partners VIII, LLC | TenPercentOwner | 2 | 2013 | ||
| INTERWEST PARTNERS VIII LP | TenPercentOwner | 2 | 2013 | ||
| Karrels James | Officer | SVP and CFO; SVP, CFO and Secretary; V P, CFO and Secretary; VP, CFO and Secretary | 36 | 2013–2026 | |
| Kliman Gilbert H | TenPercentOwner | 2 | 2013 | ||
| Koenig Scott | Director; Director,Officer | President and CEO | 30 | 2013–2026 | |
| Nadav Eran | Director | 2 | 2013 | ||
| ORONSKY ARNOLD L | Director; Director,TenPercentOwner | 4 | 2013–2014 | ||
| Risser Eric Blasius | Director,Officer; Officer | Chief Operating Officer; President and CEO; Sr VP & Chief Business Officer; SVP, Business Development; V P, Business Development; VP, Business Development | 57 | 2013–2026 | |
| Stein Kathryn E | Officer | Senior VP, Prd Dev & Reg Aff; Senior V P, Product Dev & Reg.; SVP, Product Dev. & Regulatory | 9 | 2013–2016 | |
| Stewart Stanford John | Officer | V P, Clinical Oncology | 2 | 2013 | |
| STUMP DAVID C | Director | 16 | 2013–2026 | person page Fuzzy | |
| TPG Group Holdings (SBS) Advisors, Inc. | Other; TenPercentOwner | 2 | 2013 | ||
| Wigginton Jon Marc | Officer | Senior V P, Clinical Dev.; Senior VP, Clinical Dev.; Sr V.P., Clinical; Sr VP, Clinical; Sr VP Clinical Dev & CMO; Sr VP, Clinical Dev & CMO; Sr VP, Clinical Dev. & CMO | 29 | 2013–2020 | |
| Fust Matthew K | Director | 9 | 2014–2019 | ||
| SARAN ATUL | Officer | General Counsel; See remarks; See Remarks; Sr. VP and General Counsel; SVP & General Counsel | 9 | 2014–2017 | |
| Spitznagel Thomas | Officer | Sr VP, BPD & Manufacturing; Sr VP, Technical Ops; Vice President, Development | 22 | 2016–2026 | |
| Ferrante Karen Jean | Director | 13 | 2017–2026 | ||
| Jackson Scott Thomas | Director | 13 | 2017–2026 | ||
| Peters Jeffrey Stuart | Officer | Acting General Counsel; General Counsel; Senior VP and General Counsel; Senior VP, GC, and Secretary | 26 | 2017–2026 | |
| SIEGEL JAY PHILIP | Director | 13 | 2017–2026 | ||
| Eck Stephen L. | Officer | Chief Medical Officer | 9 | 2020–2025 | |
| O'Brien Federica F. | Director | 9 | 2021–2026 | ||
| BB BIOTECH AG | TenPercentOwner | 14 | 2021–2023 | ||
| BIOTECH TARGET N V | TenPercentOwner | 14 | 2021–2023 | ||
| HEIDEN WILLIAM K | Director | 8 | 2022–2026 | ||
| Chhabra Meenu | Director | 7 | 2023–2026 | ||
| Liu Margaret | Director | 8 | 2023–2026 | ||
| Smith Beth Ann | Officer | VP, Controller & Treasurer | 6 | 2025–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Federal award recipient | MACROGENICS, INC. | MD | Federal spending (USAspending) | name and state |
| Paying company | MACROGENICS, INC. | MD | Open Payments (drug and device company payments) | name and state |
| Patent assignee | MacroGenics, Inc. | MD | Patents (USPTO) | name and state |
| SEC filer | MACROGENICS INC | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | MacroGenics, Inc. | MD | Trademarks (USPTO) | name and state |
| Person page | David C Stump MD | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, MD first:
- NORTHWEST BIOTHERAPEUTICS INC MD
- UNITED THERAPEUTICS Corp MD
- INTERCELL USA, INC. MD
- MiddleBrook Pharmaceuticals, Inc. MD
- AVALON PHARMACEUTICALS INC MD
- IGC Pharma, Inc. MD
- CNBX Pharmaceuticals Inc. MD
- PRECIGEN, INC. MD
- SUPERNUS PHARMACEUTICALS, INC. MD
- Sucampo Pharmaceuticals, Inc. MD
In other datasets, the same topic (Health) in MD:
- Nonprofit: 4K FOR CANCER INC (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health